SUMMARY Two hundred and 14 patients with chronic second degree heart block were seen and followed up in the Devon Heart Block and Bradycardia Survey between 1968 and 1982. The patients were divided into three groups according to the type of block. In group 1 there were 77 patients with Mobitz type I block (mean age 69 years), in group 2, 86 patients with Mobitz type II block (mean age 74 years), and in group 3, 51 with 2:1 or 3:1 block (mean age 75 years). The five year survival was similar in all groups, being 57%, 61%, and 53% in groups 1, 2, and 3 respectively. The presence or absence of bundle branch block did not appear to influence prognosis. In particular, patients in group 1 without bundle branch block did not fare any better than those in group 2 both with and without bundle branch block. One hundred and three of the patients were fitted with pacemakers, the proportion being greatest in group 2. In each group a significantly larger number of paced patients survived than unpaced. The five year survival for all the paced patients in the study was 78% compared with 41% for the unpaced. Since the paced patients were slightly younger than the unpaced two age matched groups of 74 patients each were selected from the paced and unpaced patients, but the five year survival of those paced was still significantly better.It is concluded that in the patients in the present study chronic Mobitz type I block has a similar prognosis to that of Mobitz type II block. Unpaced patients with both types did very badly, whereas those fitted with pacemakers had a five year survival similar to that expected for the normal population. These results refute the benign reputation of chronic Mobitz type I block and imply that patients with this condition should be considered for pacemaker implantation on similar criteria to those adopted for patients with higher degrees of block.The use of pacemakers has been a major advance in the treatment of different forms of bradycardia, and because of its dramatic effect in some groups of patients it has become the vogue. The reaction to this is the current reassessment of the place of the pacemaker in several conditions. Four years ago we produced evidence that the prognosis in chronic sinoatrial disorder (sick sinus syndrome) was not appreciably improved by pacing,' and recently the place of this form of treatment in high risk bundle branch block has been questioned.4 Second degree Mobitz type I (atrioventricular nodal) block is widely believed to be relatively benign.5-7 The corollary is that patients with this type of conduction disturbance do not require pacing in the absence of troublesome Requests for reprints to
Objective: To assess the need for pacing in adults with chronic Mobitz type I second degree atrioventricular block (Mobitz I). Design: Prospective study. Setting: District general hospital. Patients: 147 subjects aged > 20 years (age cohorts 20-44, 45-64, 65-79, and > 80) with chronic Mobitz I without second degree Mobitz II or third degree (higher degree) block on entry, seen from 1968 to 1993 and followed up to 30 June 1997. Sixty four had organic heart disease. The presence of symptomatic bradycardia was defined as highly likely in 47 patients (class 1); probable in 14 (class 2); and absent in 86 (class 3). Interventions: Pacemakers were implanted in 90 patients for the following indications: symptoms in 74 and prophylaxis in 16. Main outcome measures: The main outcome measure was death, with conduction deterioration to higher degree block or symptomatic bradycardia the alternative measure. Results: Five year survival to death was reduced in unpaced patients relative to that expected for the normal population (overall mean (SD) 53.5 (6.7)% v 68.6%, p , 0.001; class 3, 54.4 (7.3)% v 70.1%, p , 0.001). Paced patients fared better than unpaced (overall (mean (SD) five year survival 76.3 (4.5)% v 53.5 (6.7)%, p = 0.0014; class 3, 87.2 (5.4)% v 54.4 (7.3)%, p = 0.020; and organic heart disease, 68.2 (7.6)% v 44.0 (9.9)%, p ( 0.0014). There were no deaths in the , 45 cohort. Survival to first outcome (main or alternative) was further reduced to 31.7 (5.0)% in 102 patients unpaced initially and 34.2 (5.7)% in class 3. Only the 20-44 cohort and patients with sinus arrhythmia had . 50% survival. Conclusion: Mobitz I block is not usually benign in patients > 45 years of age. Pacemaker implantation should be considered, even in the absence of symptomatic bradycardia or organic heart disease.
SUMMARY Future pacemaker requirements in Britain are related to the incidence of heart block and sinoatrial disorder (sick sinus syndrome) in the community. This paper reports an 8-year survey of these conditions by direct approach to the general practitioners looking after approximately 600 000 people. The patients were divided into 4 non-exclusive groups (numbers of patients are in parentheses); chronic complete heart block (436), sinus bradycardia (potential and established sinoatrial disorder) (305), established sinoatrial disorder (131), and paced patients (209). Patients with sinoatrial disorder and sinus bradycardia were some 10 years younger than those with heart block and their prevalence tended to decline in the very old, whereas the prevalence of heart block continued to increase almost exponentially, exceeding 5 per 1000 in men aged 80 and above.Only a minority of patients gave a past history of cardiac infarction or diphtheria, but both conditions were commoner in sinoatrial disorder (16% and 14%, respectively) than in complete heart block (9% and 8%, respectively). A surprising finding was that men predominated in all groups, particularly in those with sinus bradycardia where the male:female ratio was 2-5:1. The annual number of new paced patients rose during the course of the survey, reaching 73 per million (per year) by the seventh and eighth years, but the annual incidence of conditions producing bradycardia and potentially requiring pacemaker therapy was still much greater at 159 to 174 per million of the population.In Britain the number of initial implantations of cardiac pacemakers has almost trebled since 1972 and it is predicted that there will be a further threefold increase in the next 5 years (Sowton, 1976). In view of this dramatic rise in the use of such expensive and sophisticated equipment it might be expected that the incidence and aetiology of the main conditions requiring pacemaking, namely heart block and sinoatrial disorder, would be well known, but in fact the lack of epidemiological data on heart block has been bewailed by Campbell as recently as 1977. Data on sinoatrial disorder are even more scarce (British Medical journal, 1977), while the problem is compounded by the absence of a clear-cut definition of the condition. In the past coronary artery disease was blamed for both chronic heart block and sinoatrial disorder, and if this were correct the current 'epidemic' of ischaemic heart disease should be followed by an increase in their
We describe our initial experience with a pacemaker which performs the dual function of registering episodes of cardiac arrest and pacing the heart when necessary. The apparatus has a prolonged escape interval (2.30-2.65 seconds) and is capable of counting up to 128 "events." Twenty-five patients complaining of infrequent episodes of loss of consciousness have been studied. Blackouts ceased and episodes of ventricular standstill were recorded in 14 cases; the unit helped to establish a non-cardiac etiology for the attacks in two cases. It is suggested that a bradycardia-recording facility incorporated into a programmable pacemaker would provide a much needed tool in the diagnosis and management of patients with infrequent episodes of loss of consciousness in whom a cardiac mechanism is suspected but unproven.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.